Sera Prognostics, Inc. (SERA): History, Ownership, Mission, How It Works & Makes Money

Ever wonder about the story behind Sera Prognostics, Inc. (SERA), 'The Pregnancy Company®,' and how they're working to improve maternal and neonatal health? Sera Prognostics, with a mission to provide early and pivotal pregnancy information, focuses on reducing healthcare costs and improving outcomes for mothers and newborns. Keep reading to discover how this Salt Lake City-based company operates, its financial standing, and its innovative approach to pregnancy care, especially with its PreTRM® test, which predicts the risk of premature birth.

Sera Prognostics, Inc. (SERA) History

Sera Prognostics Founding Timeline

Year established

Sera Prognostics was established in 2006.

Original location

The company was originally located in Salt Lake City, Utah.

Founding team members

The founding team included:

• Dr. Sean M. Esplin
• Dr. Brian M. Brost
• Gregory C. Critchfield, MD, MS

Initial capital/funding

Sera Prognostics secured an initial seed funding of $4.7 million in 2007. Subsequently, in 2009, they obtained $18.3 million in Series B funding. These early investments were crucial in propelling the company's research and development efforts.

Sera Prognostics Evolution Milestones

Sera Prognostics Transformative Moments

Several strategic decisions and key events have significantly shaped the trajectory of Sera Prognostics:

• Focus on Preterm Birth Prediction: The company's strategic focus on developing and commercializing the PreTRM test has been central to its identity and market position.
• Strategic Partnerships: Collaborations with major healthcare providers and payers, such as Anthem, have been crucial for expanding market access and driving adoption of the PreTRM test.
• Regulatory Milestones: Achieving Medicare coverage for the PreTRM test was a transformative moment, opening up significant reimbursement opportunities and validating the clinical utility of the test.
• Going Public: The decision to go public in 2021 provided Sera Prognostics with the financial resources to invest in further research, development, and commercialization efforts.

To gain more insight into the values that guide Sera Prognostics, you can explore: Mission Statement, Vision, & Core Values of Sera Prognostics, Inc. (SERA).

Sera Prognostics reported a net loss of $65.7 million for the year 2023. While the company has made strides in revenue, substantial operating expenses, particularly in research and development and sales and marketing, continue to impact its bottom line.

As of February 8, 2024, Sera Prognostics announced a 1-for-15 reverse stock split, which was effected on February 9, 2024. This move was intended to increase the company's stock price to regain compliance with the Nasdaq's minimum bid price requirement.

Sera Prognostics, Inc. (SERA) Ownership Structure

Sera Prognostics operates as a publicly traded company with a diverse ownership structure comprising institutional investors, individual shareholders, and company insiders.

Sera Prognostics' Current Status

Sera Prognostics, Inc. is a publicly traded company, which means its shares are available for purchase by the general public on a stock exchange. As of April 2025, it is listed on the Nasdaq Capital Market under the ticker symbol SERA.

Sera Prognostics' Ownership Breakdown

The ownership of Sera Prognostics is distributed among various types of shareholders. Data presented reflects the most current information available for the fiscal year 2024.

Sera Prognostics' Leadership

The leadership team at Sera Prognostics is responsible for guiding the company's strategic direction and overseeing its operations. As of April 2025, key members of the leadership team include:

• Matthew Stephens serves as the President and Chief Executive Officer.
• Erin Raines is the Chief Financial Officer.
• Dr. Jay Boniface is the Chief Medical Officer.

These individuals, along with other members of the executive team, bring a wealth of experience and expertise to Sera Prognostics, helping to drive innovation and growth in the field of women's health. More information about the company's mission can be found here: Mission Statement, Vision, & Core Values of Sera Prognostics, Inc. (SERA).

Sera Prognostics, Inc. (SERA) Mission and Values

Sera Prognostics is dedicated to improving maternal and infant health through innovative diagnostic testing. The company values scientific rigor, patient well-being, and collaboration to achieve its goals.

Sera Prognostics' Core Purpose

Official mission statement

Sera Prognostics' mission statement is: To improve the health of women and newborns through innovative precision medicine.

Vision statement

Sera Prognostics envisions a future where:

• Every pregnancy is healthy and full-term.
• The health of women and newborns is significantly improved through innovative diagnostic testing.
• They are the leading provider of innovative diagnostic solutions for improving maternal and infant health.

Company slogan/tagline

Sera Prognostics' tagline is 'Predicting the future of pregnancy, one test at a time.'

For more detailed information, you can visit: Mission Statement, Vision, & Core Values of Sera Prognostics, Inc. (SERA).

Sera Prognostics, Inc. (SERA) How It Works

Sera Prognostics, Inc. operates by focusing on improving maternal and infant health through innovative diagnostic testing. They develop and commercialize proprietary proteomic biomarkers and bioinformatics to provide early and reliable predictions of preterm birth risk.

Sera Prognostics' Product/Service Portfolio

Sera Prognostics' Operational Framework

Sera Prognostics focuses on:

• Biomarker Discovery and Development: Identifying and validating novel protein biomarkers associated with preterm birth.
• Clinical Validation: Conducting clinical studies to demonstrate the accuracy and reliability of their predictive tests.
• Commercialization: Marketing and selling the PreTRM test to obstetricians and maternal-fetal medicine specialists.
• Laboratory Operations: Performing the PreTRM test in their own CLIA-certified laboratory.
• Data Analysis and Reporting: Providing clinicians with clear, actionable reports based on the test results.

Sera Prognostics' Strategic Advantages

Sera Prognostics has several strategic advantages:

• Proprietary Technology: Holds patents and exclusive rights to key biomarkers and predictive algorithms.
• Clinical Evidence: Backed by multiple clinical studies demonstrating the performance and utility of the PreTRM test.
• Established Market Presence: Has secured reimbursement coverage from major insurance providers, facilitating adoption by healthcare providers.
• Focus on Unmet Need: Addresses a significant unmet need in maternal health by providing early and accurate prediction of preterm birth risk.

To gain more insights into the company's goals and guiding principles, check out: Mission Statement, Vision, & Core Values of Sera Prognostics, Inc. (SERA).

Sera Prognostics, Inc. (SERA) How It Makes Money

Sera Prognostics, Inc. focuses on improving maternal and newborn health through innovative diagnostic testing. The company primarily generates revenue by offering proprietary blood-based tests that predict the risk of preterm birth and other pregnancy complications.

Sera Prognostics, Inc.'s Revenue Breakdown

As a company focused on diagnostics, Sera Prognostics' revenue streams are centered around its proprietary tests and related services. The specifics of revenue percentages can fluctuate based on market adoption, reimbursement landscapes, and strategic partnerships.

Sera Prognostics, Inc.'s Business Economics

Sera Prognostics operates in the specialized field of predictive maternal health diagnostics. Its business economics are influenced by several factors:

• Pricing Strategy: The pricing of the PreTRM test is critical. It needs to be competitive yet reflective of the clinical value and cost savings it offers by reducing preterm birth rates and associated healthcare expenses.
• Reimbursement Landscape: A significant driver of Sera's revenue is securing favorable reimbursement policies from both private and public payers (insurance companies and government healthcare programs). Positive coverage decisions and adequate reimbursement rates are essential for widespread adoption.
• Cost of Goods Sold (COGS): Managing the costs associated with test kit production, laboratory processing, and supply chain logistics is crucial. Efficiency in these areas can significantly impact gross margins.
• Sales and Marketing Expenses: Effective marketing and sales efforts are necessary to educate healthcare providers and expectant mothers about the benefits of the PreTRM test. These expenses include direct sales force, marketing campaigns, and educational programs.
• Research and Development (R&D) Investments: Continuous investment in R&D is vital for developing new diagnostic tests and improving existing ones. These investments ensure that Sera remains at the forefront of maternal health diagnostics.

Sera Prognostics, Inc.'s Financial Performance

Analyzing Sera Prognostics' financial performance involves looking at key metrics that reflect its growth and stability.

• Revenue Growth: The rate at which Sera is increasing its revenue from PreTRM test sales and other sources is a primary indicator of its market penetration and acceptance.
• Gross Margin: This metric reflects the efficiency of Sera's operations, calculated as revenue less the cost of goods sold. A higher gross margin indicates better cost management.
• Operating Expenses: Monitoring operating expenses, including R&D, sales, and administrative costs, is essential. Keeping these expenses in check while still investing in growth is a balancing act.
• Net Loss: As a growth-stage company, Sera Prognostics has historically experienced net losses as it invests heavily in R&D and commercialization. The trend and magnitude of these losses are important for investors to watch.
• Cash Burn Rate: This metric indicates how quickly Sera is using its cash reserves. Managing the cash burn rate is crucial for ensuring the company has sufficient runway to reach profitability or secure additional funding.

For additional insights into Sera Prognostics, Inc., you might find this resource helpful: Exploring Sera Prognostics, Inc. (SERA) Investor Profile: Who’s Buying and Why?

Sera Prognostics, Inc. (SERA) Market Position & Future Outlook

Sera Prognostics is navigating a challenging yet promising landscape, focusing on improving women's health through innovative diagnostic testing. Their market position is carved out by specialized offerings in predicting preterm birth, addressing a critical unmet need in maternal healthcare. Future outlook involves strategic expansions and partnerships to enhance market penetration and adoption of their key products.

Competitive Landscape

The competitive landscape for Sera Prognostics involves a mix of specialized diagnostic companies and broader healthcare service providers. While precise, up-to-date market share data as of April 2025 is difficult to ascertain without access to proprietary market research, we can outline a likely scenario based on available industry information.

Opportunities & Challenges

Sera Prognostics faces a dynamic set of opportunities and challenges that will shape its trajectory in the maternal health diagnostics market.

Industry Position

Sera Prognostics occupies a unique position within the maternal health diagnostics industry. Here are key aspects of their industry standing:

• Niche Specialization: Focus on preterm birth prediction sets them apart.
• Technological Edge: The PreTRM® test offers a proprietary, risk prediction.
• Growth Potential: Opportunities to expand through partnerships and market awareness initiatives.

To gain more insights into Sera Prognostics' financial health, consider exploring this resource: Breaking Down Sera Prognostics, Inc. (SERA) Financial Health: Key Insights for Investors